个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Jianbo Tian[1] * ; Xianglin Yuan[3] * ; Jun Xiao[4] * ; Qiang Zhong[5] * ; Chunguang Yang[4] * ; Bo Liu[3] * ; Yimin Cai[1] * ; Zequn Lu[1] * ; Jing Wang[4] ; Yanan Wang[4] ; Shuanglin Liu[9] ; Biao Cheng[10] ; Jin Wang[12] ; Ming Zhang[1] ; Lu Wang[1] ; Siyuan Niu[1] ; Zhi Yao[14] ; Xiongbo Deng[15] ; Fan Zhou[16] ; Wei Wei[17] ; Qinglin Li[18] ; Xin Chen[3] ; Wenqiong Chen[4] ; Qin Yang[6] ; Shiji Wu[7] ; Jiquan Fan[13] ; Bo Shu[11] ; Zhiquan Hu[4] ; Shaogang Wang[4] ; Xiang-Ping Yang[2] ; Wenhua Liu[8] ; Xiaoping Miao[1] ; Zhihua Wang[4,*1] ;
单位： [1]Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [2]Department of Immunology,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [3]Department of Oncology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [4]Department of Urology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [5]Department of Critical Care Medicine,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [6]Department of Pathology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [7]Department of Laboratory Medicine,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [8]Clinical Research Center,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [9]Department of Urology, Wuhan First Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [10]Department of Pharmacy,The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [11]Department of Urology,The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [12]Department of Urology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [13]Department of Oncology,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [14]Department of Respirology and Tuberculosis Specialty, Wuhan Pulmonary Hospital, Wuhan, China [15]Department of Radiology, Wuhan Jinyintan Hospital, Wuhan, China [16]Department of Urology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [17]Department of Urology, The Fifth Hospital of Wuhan, Wuhan, China [18]Department of Respiratory Medicine, Wuhan Hankou Hospital, Wuhan, China
出处：
DOI： 10.1016/S1470-2045(20)30309-0
ISSN：

摘要：
Background: COVID-19 has spread globally. Epidemiological susceptibility to COVID-19 has been reported in patients with cancer. We aimed to systematically characterise clinical features and determine risk factors of COVID-19 disease severity for patients with cancer and COVID-19. Methods: In this multicentre, retrospective, cohort study, we included all adult patients (aged ≥18 years) with any type of malignant solid tumours and haematological malignancy who were admitted to nine hospitals in Wuhan, China, with laboratory-confirmed COVID-19 between Jan 13 and March 18, 2020. Enrolled patients were statistically matched (2:1) with patients admitted with COVID-19 who did not have cancer with propensity score on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, illness severity, and clinical interventions were compared between patients with COVID-19 with or without cancer as well as between patients with cancer with non-severe or severe COVID-19. COVID-19 disease severity was defined on admission on the basis of the WHO guidelines. Univariable and multivariable logistic regression, adjusted for age, sex, comorbidities, cancer type, tumour stage, and antitumour treatments, were used to explore risk factors associated with COVID-19 disease severity. This study was registered in the Chinese Clinical Trial Register, ChiCTR2000030807. Findings: Between Jan 13 and March 18, 2020, 13 077 patients with COVID-19 were admitted to the nine hospitals in Wuhan and 232 patients with cancer and 519 statistically matched patients without cancer were enrolled. Median follow-up was 29 days (IQR 22–38) in patients with cancer and 27 days (20–35) in patients without cancer. Patients with cancer were more likely to have severe COVID-19 than patients without cancer (148 [64%] of 232 vs 166 [32%] of 519; odds ratio [OR] 3·61 [95% CI 2·59–5·04]; p<0·0001). Risk factors previously reported in patients without cancer, such as older age; elevated interleukin 6, procalcitonin, and D-dimer; and reduced lymphocytes were validated in patients with cancer. We also identified advanced tumour stage (OR 2·60, 95% CI 1·05–6·43; p=0·039), elevated tumour necrosis factor α (1·22, 1·01–1·47; p=0·037), elevated N-terminal pro-B-type natriuretic peptide (1·65, 1·03–2·78; p=0·032), reduced CD4+ T cells (0·84, 0·71–0·98; p=0·031), and reduced albumin–globulin ratio (0·12, 0·02–0·77; p=0·024) as risk factors of COVID-19 severity in patients with cancer. Interpretation: Patients with cancer and COVID-19 were more likely to deteriorate into severe illness than those without cancer. The risk factors identified here could be helpful for early clinical surveillance of disease progression in patients with cancer who present with COVID-19. Funding: China National Natural Science Foundation. © 2020 Elsevier Ltd

基金：
This work is supported by the China National Natural Science Foundation (grant number 81974400). We thank all patients and their families involved in the study and all health-care workers who are working against COVID-19. We also thank David Horne (City of Hope, CA, USA), Hui Zhu (Cleveland Clinic Foundation, OH, USA), Gonghong Wei (University of Oulu, Finland), and Jiping Wang (Northwestern University, IL, USA) for their assistance.

基金编号： 81974400

语种：
外文
高被引：
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2018]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者单位： [1]Department of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
共同第一作者：
通讯作者：
通讯机构： [4]Department of Urology,Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [*1]Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
推荐引用方式(GB/T 7714)：
Jianbo Tian,Xianglin Yuan,Jun Xiao,et al.Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study [J].LANCET ONCOLOGY.2020,21(7):893-903.doi:10.1016/S1470-2045(20)30309-0.
APA：
Jianbo Tian,Xianglin Yuan,Jun Xiao,Qiang Zhong,Chunguang Yang...&Zhihua Wang.(2020).Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study .LANCET ONCOLOGY,21,(7)
MLA：
Jianbo Tian,et al."Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study ".LANCET ONCOLOGY 21..7(2020):893-903

资源点击量：432 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）